Nichole Escalante
Senior Scientist & Group Lead, In Vivo Pharmacology & PK Zymeworks
Dr. Nichole Escalante is Senior Scientist and Group Lead of In Vivo Pharmacology and Pharmacokinetics at Zymeworks, working within the Multispecific Antibody Therapeutic division. She leads preclinical development for diverse modalities including T cell engagers, bi/trispecific antibodies, and engineered cytokines. Her team manages all mouse modeling, from syngeneic and PBMC models to PDX systems, alongside pharmacokinetic assay development and execution. An immunologist with 15+ years of experience in immune-related diseases and cancer, Dr. Escalante specializes in flow cytometry, immune cell profiling, in vitro assay development, and translational model design for complex therapeutic platforms.
Seminars
- Incorporating CD28 co-stimulation with DLL3 and CD3 engagement to enhance T cell activation, proliferation, and sustained cytotoxicity beyond bispecific benchmarks
- Demonstrating superior in vitro and in vivo anti-tumor activity through serial challenge assays and xenograft models that highlight efficacy and T cell fitness
- Establishing translational confidence with PK, cytokine release, and safety profiling in primates to support clinical development of ZW209 in DLL3-positive cancers
